Magnitude of end-stage renal disease in IDDM: A 35 year follow-up study

被引:119
作者
Krolewski, M
Eggers, PW
Warram, JH
机构
[1] JOSLIN DIABET CTR,EPIDEMIOL & GENET SECT,BOSTON,MA 02215
[2] HARVARD UNIV,SCH PUBL HLTH,DEPT EPIDEMIOL,BOSTON,MA 02115
[3] US HLTH CARE FINANCING ADM,RES OFF,BALTIMORE,MD 21207
关键词
D O I
10.1038/ki.1996.527
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Significant improvements were made during the last two decades in the treatment of IDDM patients. To assess the risk of ESRD in a population that was exposed to these improvements, we determined the cumulative incidence of ESRD in a cohort of 142 white patients who were aged less than 21 years when they came to the Joslin Diabetes Center in 1959 with recently diagnosed IDDM. The first case of ESRD occurred after 13 years of IDDM, and a total of 25 cases have developed by 35 years' duration (cumulative incidence 21.3%). Median survival after the diagnosis Of ESRD for the 16 patients who began dialysis was only 3.5 years. A strong predictor of the development of ESRD was the level of glycemic control during the first two decades of IDDM. ESRD developed in 36.3% of patients in the worst tertile for glycemic control but only in 14.4% and 9.2% of those in the middle and best tertiles. In comparison with two population based studies, the onset of ESRD in the Joslin Cohort was postponed by about five years. This advantage is more plausibly attributable to differences arising after the diagnosis of diabetes than to referral of less severe cases of IDDM to the Joslin Diabetes Center. What differences in diabetes care accounted for the postponement of ESRD cannot be discerned from comparisons among published studies, but likely candidates include Joslin's long-term advocacy of good glycemic control and the prompt implementation of new clinical interventions, such as antihypertensive treatment.
引用
收藏
页码:2041 / 2046
页数:6
相关论文
共 24 条
[1]  
ANDERSEN AR, 1983, DIABETOLOGIA, V25, P496
[2]   DECLINING INCIDENCE OF NEPHROPATHY IN INSULIN-DEPENDENT DIABETES-MELLITUS [J].
BOJESTIG, M ;
ARNQVIST, HJ ;
HERMANSSON, G ;
KARLBERG, BE ;
LUDVIGSSON, J .
NEW ENGLAND JOURNAL OF MEDICINE, 1994, 330 (01) :15-18
[3]  
BORCHJOHNSEN K, 1986, DIABETES RES CLIN EX, V3, P397
[4]   DIABETES AND HYPERTENSIVE VASCULAR-DISEASE - MECHANISMS AND TREATMENT [J].
CHRISTLIEB, AR .
AMERICAN JOURNAL OF CARDIOLOGY, 1973, 32 (04) :592-606
[5]   RAPID METHOD FOR DETERMINATION OF GLYCOSYLATED HEMOGLOBINS USING HIGH-PRESSURE LIQUID-CHROMATOGRAPHY [J].
COLE, RA ;
SOELDNER, JS ;
DUNN, PJ ;
BUNN, HF .
METABOLISM-CLINICAL AND EXPERIMENTAL, 1978, 27 (03) :289-301
[6]   DISPARITIES IN INCIDENCE OF DIABETIC END-STAGE RENAL-DISEASE ACCORDING TO RACE AND TYPE OF DIABETES [J].
COWIE, CC ;
PORT, FK ;
WOLFE, RA ;
SAVAGE, PJ ;
MOLL, PP ;
HAWTHORNE, VM .
NEW ENGLAND JOURNAL OF MEDICINE, 1989, 321 (16) :1074-1079
[7]  
*DCCT RES GROUP, 1993, NEW ENGL J MED, V329, P977
[8]   CLINIC ATTENDANCE AND GLYCEMIC CONTROL - STUDY OF CONTRASTING GROUPS OF PATIENTS WITH IDDM [J].
JACOBSON, AM ;
ADLER, AG ;
DERBY, L ;
ANDERSON, BJ ;
WOLFSDORF, JI .
DIABETES CARE, 1991, 14 (07) :599-601
[9]  
JACOBSON AM, UNPUB CONTEXTS CONSE
[10]   Screening to prevent renal failure in insulin dependent diabetic patients: An economic evaluation [J].
Kiberd, BA ;
Jindal, KK .
BRITISH MEDICAL JOURNAL, 1995, 311 (7020) :1595-1599